TMS Research: What Changed in 2026
· Updated November 2026 · Aazaz Haq, MD
I follow TMS research closely because it changes what we can offer patients. Here are the developments from 2026 that I think are most useful for people considering treatment, along with what is still unproven.
The short answer
In 2026, the FDA cleared accelerated TMS protocols on MagVenture systems, allowing a course in days rather than weeks, and cleared an EEG-guided form of TMS for PTSD. Theta burst stimulation and real-world outcomes have held up well. Imaging-guided targeting and long-term durability of accelerated courses still need more research.
Accelerated TMS became broadly available
In May 2026, the FDA cleared accelerated TMS protocols for depression on MagVenture systems, the machines we use. Accelerated means more than one session a day, from 2 to 10, so a course can be completed in days rather than six weeks. The clearance was based on a systematic review showing outcomes comparable to standard once-daily treatment, without an increase in side effects.
This builds on earlier work, including a Stanford-developed protocol cleared in 2022 that delivers ten sessions a day for five days. The practical meaning for patients: fewer weeks of daily visits for people who cannot manage them. I explain the details in Accelerated TMS for Depression.
TMS cleared for PTSD
In June 2026, the FDA cleared an EEG-guided form of TMS, delivered on MagVenture equipment, as an add-on treatment for post-traumatic stress disorder in adults. It is the first TMS-based treatment cleared for PTSD, and it uses each person's brain-wave recording to set the stimulation. We do not currently offer it, but it is a sign of where the field is heading: more personalized targeting and more conditions.
What has held up
- Theta burst stimulation, which takes about 3 minutes instead of about 19, continues to perform as well as standard stimulation for depression.
- Real-world results remain consistent with earlier studies: about 6 in 10 people respond to a course and nearly 4 in 10 reach remission.
- Safety remains strong. Headache and scalp discomfort are common early on; seizure is rare, about 1 in 30,000 sessions.
What is still unproven
Brain-imaging-guided targeting is promising, but most clinics do not have it, and we do not yet know how much it improves results in everyday practice. We also have limited long-term data on how long accelerated courses keep people well. Research on TMS for conditions like dementia, chronic pain and addiction is active but early. I am careful not to offer things the evidence does not yet support.
What this means for you
If you were put off by the six-week schedule, it may be worth another look. If you tried TMS years ago and partly responded, newer protocols may be an option. Our TMS guide covers the basics, and you can request a consultation call to talk about your situation.
Questions I hear often
Should I wait for newer TMS methods?
Usually not. Standard and theta burst TMS are well established, widely covered and effective for many people. Waiting for a future method means more time with depression now. If newer protocols become clearly better, people who responded partly can often benefit from them later.
Do you offer brain-imaging-guided TMS?
Not at this time. We use careful measurement on the first day to locate the treatment target and set the strength, which is how most clinics practice and how most of the evidence was gathered.
Will insurance cover accelerated TMS now?
Coverage policies usually lag behind FDA clearances. Our accelerated protocol is self-pay. Standard and theta burst courses are covered by most plans.
How I read new research
I try to apply the same standards to new findings that I would want applied to my own care. Was it a randomized trial, or an observational study? How many people were studied? Were results measured carefully, and over how long? Who funded it? Small studies and press releases are a starting point, not a conclusion. When something changes what we should offer, we change our practice. When it does not yet, I say so plainly.
References
- U.S. FDA 510(k) K260189. MagVenture Accelerated TMS (aTMS) Therapy System. May 2026. Source
- MagVenture. FDA clearance of Wave Neuroscience's MeRT system for PTSD, delivered on MagVenture technology. June 2026. Source
- Cole EJ, et al. Stanford Neuromodulation Therapy (SNT): a double-blind randomized controlled trial. Am J Psychiatry. 2022. PubMed
- Blumberger DM, et al. Theta burst versus high-frequency rTMS in depression (THREE-D). Lancet. 2018. PubMed